Compare Ascendis Pharma A/S (ASND) vs Southwest Airlines Co (LUV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Southwest Airlines Co — how do they compare? Ascendis Pharma A/S trades at $264.44 (market cap $17.74B), while Southwest Airlines Co trades at $48.06 (market cap $23.67B). The key difference: Southwest Airlines Co is the larger of the two by market cap, and Southwest Airlines Co pays a 1.49% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | LUV | |
|---|---|---|
Market Cap | $17.74B | $23.67B |
Sector | Health | Industrials |
52-Week High | $277.18 | $54.80 |
52-Week Low | $163.32 | $29.06 |
Enterprise Value | $18.11B | $26.74B |
Dividend Yield | — | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Southwest Airlines (LUV) trades at $48.43, down 1.61% today, with a bullish technical signal from moving averages and RSI near oversold levels. The company reported mixed Q1 2026 earnings, missing estimates, but maintains a positive outlook with Q2 2026 EPS expected at $0.52. Recent news highlights sector tailwinds from lower fuel costs and a partnership with AWS to accelerate AI capabilities by 2028.
LUV presents a balanced risk-reward profile with a consensus price target of $52.47, offering ~8% upside. Key opportunities include earnings growth potential and favorable industry dynamics, while risks involve Boeing 737 MAX incidents and volatile fuel prices. Analyst sentiment is mixed, with 42% buy ratings, reflecting cautious optimism amid operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →
